Norges Bank Invests $114.37 Million in Madrigal Pharmaceuticals, Inc. $MDGL

Posted by George Bondi on Jun 5th, 2026

Norges Bank bought a new stake in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Free Report) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 196,393 shares of the biopharmaceutical company’s stock, valued at approximately $114,368,000.

Other large investors also recently made changes to their positions in the company. Wellington Management Group LLP grew its holdings in shares of Madrigal Pharmaceuticals by 5,381.2% in the third quarter. Wellington Management Group LLP now owns 404,455 shares of the biopharmaceutical company’s stock valued at $185,507,000 after acquiring an additional 397,076 shares in the last quarter. Baker BROS. Advisors LP increased its position in shares of Madrigal Pharmaceuticals by 8.4% during the third quarter. Baker BROS. Advisors LP now owns 2,141,701 shares of the biopharmaceutical company’s stock valued at $982,313,000 after acquiring an additional 165,683 shares during the last quarter. Alkeon Capital Management LLC bought a new stake in Madrigal Pharmaceuticals during the third quarter worth $55,039,000. Invesco Ltd. lifted its holdings in Madrigal Pharmaceuticals by 49.5% during the third quarter. Invesco Ltd. now owns 299,565 shares of the biopharmaceutical company’s stock worth $137,398,000 after acquiring an additional 99,209 shares during the period. Finally, BNP Paribas Financial Markets boosted its position in Madrigal Pharmaceuticals by 1,886.1% in the second quarter. BNP Paribas Financial Markets now owns 69,037 shares of the biopharmaceutical company’s stock worth $20,893,000 after purchasing an additional 65,561 shares during the last quarter. 98.50% of the stock is owned by institutional investors.

Madrigal Pharmaceuticals Stock Performance

NASDAQ:MDGL opened at $492.83 on Friday. The company has a market capitalization of $11.36 billion, a P/E ratio of -38.50 and a beta of -1.07. The business has a fifty day simple moving average of $516.40 and a two-hundred day simple moving average of $514.12. The company has a debt-to-equity ratio of 0.63, a current ratio of 3.50 and a quick ratio of 3.16. Madrigal Pharmaceuticals, Inc. has a 1 year low of $271.95 and a 1 year high of $615.00.

Madrigal Pharmaceuticals (NASDAQ:MDGL – Get Free Report) last issued its quarterly earnings results on Wednesday, May 6th. The biopharmaceutical company reported ($3.25) EPS for the quarter, beating analysts’ consensus estimates of ($3.61) by $0.36. Madrigal Pharmaceuticals had a negative return on equity of 50.15% and a negative net margin of 27.32%.The firm had revenue of $311.34 million for the quarter, compared to analysts’ expectations of $301.05 million. During the same quarter in the prior year, the firm earned ($3.32) EPS. The business’s revenue for the quarter was up 126.8% compared to the same quarter last year. On average, analysts expect that Madrigal Pharmaceuticals, Inc. will post -7.23 earnings per share for the current year.

Insider Activity

In other news, Director Richard S. Levy sold 5,682 shares of the business’s stock in a transaction that occurred on Friday, May 22nd. The shares were sold at an average price of $515.44, for a total value of $2,928,730.08. Following the sale, the director owned 22,015 shares of the company’s stock, valued at $11,347,411.60. The trade was a 20.51% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider David Soergel sold 1,042 shares of the company’s stock in a transaction that occurred on Monday, June 1st. The shares were sold at an average price of $495.74, for a total transaction of $516,561.08. Following the sale, the insider owned 10,033 shares in the company, valued at $4,973,759.42. The trade was a 9.41% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 7,568 shares of company stock worth $3,880,711. Insiders own 17.60% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on MDGL. Bank of America reduced their price objective on Madrigal Pharmaceuticals from $570.00 to $529.00 and set a “neutral” rating for the company in a research note on Friday, February 20th. Zacks Research raised shares of Madrigal Pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on Friday, February 20th. Truist Financial increased their price target on shares of Madrigal Pharmaceuticals from $640.00 to $709.00 and gave the company a “buy” rating in a research report on Wednesday, May 13th. Evercore set a $649.00 price objective on shares of Madrigal Pharmaceuticals in a report on Thursday, May 7th. Finally, Citigroup reaffirmed a “market outperform” rating on shares of Madrigal Pharmaceuticals in a research report on Monday. One research analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, three have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $687.00.

Read Our Latest Analysis on Madrigal Pharmaceuticals

Madrigal Pharmaceuticals Company Profile

(Free Report)

Madrigal Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the development of innovative therapies for cardiovascular, metabolic and liver diseases. The company’s pipeline centers on novel, liver-directed agents designed to address significant unmet medical needs, with an emphasis on nonalcoholic steatohepatitis (NASH) and related metabolic disorders.

The lead product candidate, resmetirom (MGL-3196), is an orally administered, selective thyroid hormone receptor-β agonist in Phase 3 development for the treatment of NASH.